Unknown

Dataset Information

Gene Therapy for High Grade Glioma: The Clinical Experience.


ABSTRACT:

Introduction

High-grade gliomas (HGG) are the most common malignant primary brain tumors in adults, with a median survival of ~18 months. The standard of care (SOC) is maximal safe surgical resection, and radiation therapy with concurrent and adjuvant temozolomide. This protocol remains unchanged since 2005, even though HGG median survival has marginally improved.

Areas covered

Gene therapy was developed as a promising approach to treat HGG. Here, we review completed and ongoing clinical trials employing viral and non-viral vectors for adult and pediatric HGG, as well as the key supporting preclinical data.

Expert opinion

These therapies have proven safe, and pre- and post-treatment tissue analyses demonstrated tumor cell lysis, increased immune cell infiltration, and

SUBMITTER: Varela ML 

PROVIDER: S-EPMC9998375 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature